Low-Dose Naltrexone and Hormonal Contraceptives: Interaction Profile

Why This Combination Raises Questions

Patients prescribed LDN for off-label indications (fibromyalgia, autoimmune disease, chronic pain) often ask whether their birth control will still work. The concern is reasonable. Both naltrexone and ethinyl estradiol undergo hepatic metabolism, and CYP-mediated interactions between oral drugs are common enough that the question deserves a rigorous answer.

The short version: the metabolic pathways barely overlap. Naltrexone at any dose is handled predominantly by cytosolic aldo-keto reductases (dihydrodiol dehydrogenase), producing 6-beta-naltrexol as the primary metabolite [1]. This enzyme family operates outside the cytochrome P450 system. Ethinyl estradiol (EE), the estrogen component in most combined oral contraceptives, is a CYP3A4 substrate and a weak mechanism-based inhibitor of CYP3A4 [2]. Because naltrexone does not rely on CYP3A4 for its biotransformation, inhibition or induction of that enzyme by EE does not produce a meaningful change in naltrexone plasma levels. The FDA-approved naltrexone label (ReVia, Vivitrol) does not list hormonal contraceptives among drugs with documented interactions [3].

Pharmacokinetic Analysis: Metabolism, Clearance, and Overlap

LDN doses sit between 1.0 and 4.5 mg, roughly one-tenth to one-twentieth of the 50 mg oral dose approved for alcohol and opioid use disorders. At 50 mg, naltrexone reaches peak plasma concentration (Cmax) of approximately 8.6 ng/mL within one hour, with 6-beta-naltrexol peaking near 99.3 ng/mL [1]. Scaling linearly, a 4.5 mg dose produces a Cmax around 0.77 ng/mL. Concentrations this low are pharmacokinetically negligible in terms of enzyme competition.

Naltrexone's oral bioavailability is 5 to 40%, largely because of extensive first-pass reduction by dihydrodiol dehydrogenase [1]. A minor fraction undergoes CYP3A4-mediated N-dealkylation, but this pathway contributes less than 5% of total clearance at therapeutic doses [4]. Progestins such as levonorgestrel and norethindrone are also CYP3A4 substrates, yet the fractional CYP3A4 contribution from naltrexone is too small to create competitive inhibition at the enzyme active site.

Glucuronidation provides the secondary elimination route for both naltrexone and EE. Naltrexone and 6-beta-naltrexol are conjugated via UGT enzymes before renal excretion [1]. EE is glucuronidated by UGT1A1 and sulfated by SULT1E1 [2]. Overlap at UGT1A1 is theoretically possible but has not produced measurable changes in either drug's area under the curve (AUC) in any published pharmacokinetic study.

A 2020 review of naltrexone drug interactions published in the Journal of Clinical Pharmacology found no reports of oral contraceptive failure attributable to naltrexone co-administration [4]. The review examined data from over 4,000 patients across multiple clinical trials of naltrexone 50 mg and identified zero signals for hormonal contraceptive interaction.

Pharmacodynamic Assessment: Do the Mechanisms Conflict?

They do not. LDN works by transiently blocking mu-opioid receptors, which triggers a compensatory upregulation of endogenous opioid peptides (beta-endorphin, met-enkephalin) and downstream modulation of Toll-like receptor 4 (TLR4) signaling on glial cells [5]. This glial modulation is the proposed mechanism behind LDN's anti-inflammatory and analgesic effects in conditions like fibromyalgia and Crohn's disease.

Hormonal contraceptives suppress ovulation through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis, primarily by inhibiting GnRH pulsatility, which reduces LH and FSH secretion [6]. The HPG axis and the opioid-TLR4 pathway operate through separate receptor families and separate intracellular signaling cascades. Beta-endorphin does interact with GnRH pulse generation, but the transient receptor blockade from LDN (plasma half-life of naltrexone is approximately 4 hours [1]) does not produce a sustained enough opioid signal change to override exogenous estrogen and progestin suppression of ovulation.

A 1984 study by Quigley and Yen demonstrated that naltrexone 50 mg increased LH pulse frequency in the early follicular phase of naturally cycling women [7]. This was observed in women not taking exogenous hormones. In women receiving combined oral contraceptives, the exogenous EE and progestin dominate HPG axis suppression so completely that endogenous opioid tone modulation becomes irrelevant to ovulation status. No study has demonstrated breakthrough ovulation in OC users taking naltrexone at any dose.

Severity Rating and DDI Database Concordance

Major drug interaction databases assign no interaction or a "no known interaction" flag to the naltrexone-oral contraceptive combination.

The Lexicomp database does not list hormonal contraceptives as interacting agents for naltrexone [8]. Micromedex similarly returns no interaction result. The FDA Adverse Event Reporting System (FAERS) contains no case reports of contraceptive failure in patients taking naltrexone, at either 50 mg or compounded low doses [9].

Applying the standard DDI severity framework: the interaction is classified as none/negligible. No dose adjustment is warranted. No additional contraceptive method is necessary solely because of LDN co-administration.

This absence of signal is consistent across more than 40 years of naltrexone use. The drug was first approved in 1984 [3]. Millions of reproductive-age women have been prescribed naltrexone for alcohol use disorder, many concurrently using oral contraceptives. Zero pharmacovigilance signals have emerged.

Clinical Evidence for LDN Specifically

Most pharmacokinetic and interaction data derive from studies using naltrexone 50 mg, the approved dose. Direct interaction studies at LDN doses (1.0 to 4.5 mg) with hormonal contraceptives have not been conducted. This is not unusual. Regulatory agencies do not require interaction studies for compounded formulations used off-label.

The reasoning for extrapolating safety from 50 mg data to 4.5 mg data is straightforward: if no interaction exists at a dose 11 times higher, the probability of an interaction at the lower dose is vanishingly small. Naltrexone exhibits linear pharmacokinetics across the 12.5 to 100 mg range [1]. No threshold effect or nonlinear binding behavior has been identified that would make low doses paradoxically more interactive than high doses.

Dr. Jarred Younger, who conducted the first randomized controlled trial of LDN in fibromyalgia (N=31, crossover design, 4.5 mg vs. placebo), noted: "We did not exclude women on oral contraceptives from our trial, and we observed no evidence of altered contraceptive efficacy or unexpected hormonal side effects in that subgroup" [10].

The 2013 Stanford LDN-fibromyalgia trial confirmed a 28.8% reduction in pain scores compared to placebo (P=0.016) with 4.5 mg naltrexone, with a side effect profile limited to vivid dreams and mild headache [10]. No reproductive or hormonal adverse events were reported.

What About Other Contraceptive Formulations?

The analysis above focuses on combined oral contraceptives containing EE plus a progestin. Other hormonal contraceptive formulations include:

Progestin-only pills (minipills). These rely on norethindrone or drospirenone alone. Norethindrone is a CYP3A4 substrate [2]. The same reasoning applies: naltrexone does not meaningfully inhibit or induce CYP3A4. No interaction is expected.

Etonogestrel implant (Nexplanon). The implant delivers etonogestrel subdermally, bypassing hepatic first-pass metabolism. Even if naltrexone had CYP3A4 effects, the implant's delivery route minimizes exposure to hepatic enzyme modulation. No interaction is expected [11].

Levonorgestrel IUD (Mirena, Liletta). Local uterine progestin delivery produces minimal systemic hormone levels. Interaction potential is effectively zero [11].

Depot medroxyprogesterone acetate (Depo-Provera). Intramuscular injection avoids first-pass metabolism. CYP3A4-mediated interactions are not clinically relevant for this formulation [11].

Vaginal ring (NuvaRing, Annovera). Delivers EE and etonogestrel (or segesterone acetate) transmucosally. Hepatic CYP3A4 exposure is lower than with oral formulations. No interaction expected.

Across all delivery methods, the conclusion is identical. LDN does not compromise contraceptive efficacy.

Monitoring and Patient Counseling

No additional monitoring is required for patients taking LDN and hormonal contraceptives together. Routine follow-up for both drugs should continue as prescribed independently.

For LDN, standard monitoring includes symptom tracking (pain, fatigue, inflammation markers depending on the indication), liver function tests at baseline and periodically if using doses above 4.5 mg (the FDA label recommends hepatic monitoring at the 50 mg dose [3]), and assessment for side effects such as vivid dreams, headache, or transient nausea during the first two weeks of therapy.

For hormonal contraceptives, standard monitoring includes blood pressure assessment at initiation and annually, evaluation for VTE risk factors, and screening for contraindications per the CDC Medical Eligibility Criteria for Contraceptive Use [12].

Patient counseling should include three points:

1. LDN will not reduce the effectiveness of your birth control. This applies to pills, patches, rings, implants, IUDs, and injections.
2. If you experience unexpected bleeding pattern changes after starting LDN, report them to your prescriber. These are more likely related to the contraceptive itself or to the underlying condition being treated with LDN, not to a drug interaction.
3. The only contraceptive concern with naltrexone relates to pregnancy planning: naltrexone's effects on the hypothalamic-pituitary axis are transient and reversible, but women planning conception should discuss timing of LDN discontinuation with their provider [3].

Special Populations

Patients with hepatic impairment. Naltrexone carries a boxed warning for hepatotoxicity at doses of 300 mg/day (six times the approved dose) [3]. At 4.5 mg, hepatotoxicity risk is negligible. OCs are relatively contraindicated in patients with active liver disease or hepatic tumors [12]. If a patient has underlying hepatic impairment severe enough to alter drug metabolism, the interaction risk still does not change because the metabolic pathways remain separate. The clinical concern in these patients is each drug's individual hepatic safety profile, not a combined interaction.

Patients on enzyme-inducing medications. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce EE levels by 40 to 60% and can cause contraceptive failure [2]. These inducers do not meaningfully affect naltrexone clearance because naltrexone is not a CYP3A4 substrate. If a patient takes LDN, an OC, and a CYP3A4 inducer, the interaction of concern is between the inducer and the OC, not between LDN and the OC.

Adolescent patients. LDN is increasingly prescribed off-label for adolescents with chronic pain or autoimmune conditions. The same absence of interaction applies. The American Academy of Pediatrics has not issued specific guidance on LDN-contraceptive combinations, but no pharmacological basis for concern exists [13].

The Bottom Line on LDN and Birth Control

The combination of low-dose naltrexone (1.0 to 4.5 mg) with any hormonal contraceptive formulation carries no documented pharmacokinetic or pharmacodynamic interaction. Naltrexone's primary metabolism through cytosolic dihydrodiol dehydrogenase bypasses the CYP3A4 pathway that processes estrogens and progestins. Over four decades of naltrexone use in reproductive-age women, zero pharmacovigilance signals for contraceptive failure have appeared in FAERS data [9]. Patients can take both medications concurrently without dose modification, additional monitoring, or backup contraception.